Terms: = Prostate cancer AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Prognosis
14 results:
1. Evaluation of Matrix Metalloproteases by Artificial Intelligence Techniques in Negative Biopsies as New Diagnostic Strategy in prostate cancer.
Eiro N; Medina A; Gonzalez LO; Fraile M; Palacios A; Escaf S; Fernández-Gómez JM; Vizoso FJ
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108185
[TBL] [Abstract] [Full Text] [Related]
2. RUNX1 Is Regulated by Androgen Receptor to Promote cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast cancer.
Fernández NB; Sosa SM; Roberts JT; Recouvreux MS; Rocha-Viegas L; Christenson JL; Spoelstra NS; Couto FL; Raimondi AR; Richer JK; Rubinstein N
Cells; 2023 Jan; 12(3):. PubMed ID: 36766786
[TBL] [Abstract] [Full Text] [Related]
3. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Armstrong AJ; Nixon AB; Carmack A; Yang Q; Eisen T; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; George DJ; Halabi S
Clin Cancer Res; 2021 Jun; 27(12):3317-3328. PubMed ID: 33593885
[TBL] [Abstract] [Full Text] [Related]
4. Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Jiang WG; Sanders AJ; Katoh M; Ungefroren H; Gieseler F; Prince M; Thompson SK; Zollo M; Spano D; Dhawan P; Sliva D; Subbarayan PR; Sarkar M; Honoki K; Fujii H; Georgakilas AG; Amedei A; Niccolai E; Amin A; Ashraf SS; Ye L; Helferich WG; Yang X; Boosani CS; Guha G; Ciriolo MR; Aquilano K; Chen S; Azmi AS; Keith WN; Bilsland A; Bhakta D; Halicka D; Nowsheen S; Pantano F; Santini D
Semin Cancer Biol; 2015 Dec; 35 Suppl():S244-S275. PubMed ID: 25865774
[TBL] [Abstract] [Full Text] [Related]
5. Effects of eicosapentaenoic acid and docosahexaenoic acid on prostate cancer cell migration and invasion induced by tumor-associated macrophages.
Li CC; Hou YC; Yeh CL; Yeh SL
PLoS One; 2014; 9(6):e99630. PubMed ID: 24925287
[TBL] [Abstract] [Full Text] [Related]
6. Expression of MMP-1, MMP-9 and timp-2 in prostate carcinoma and their influence on prognosis and survival.
Ozden F; Saygin C; Uzunaslan D; Onal B; Durak H; Aki H
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1373-82. PubMed ID: 23708302
[TBL] [Abstract] [Full Text] [Related]
7. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder cancer.
Reis ST; Leite KR; Piovesan LF; Pontes-Junior J; Viana NI; Abe DK; Crippa A; Moura CM; Adonias SP; Srougi M; Dall'Oglio MF
BMC Urol; 2012 Jun; 12():18. PubMed ID: 22695075
[TBL] [Abstract] [Full Text] [Related]
8. Underexpression of MMP-2 and its regulators, timp2, MT1-MMP and IL-8, is associated with prostate cancer.
Reis ST; Antunes AA; Pontes-Junior J; Sousa-Canavez JM; Dall'Oglio MF; Piantino CB; Cruz JA; Morais DR; Srougi M; Leite KR
Int Braz J Urol; 2012; 38(2):167-74. PubMed ID: 22555040
[TBL] [Abstract] [Full Text] [Related]
9. MMP-9 overexpression due to timp-1 and RECK underexpression is associated with prognosis in prostate cancer.
Reis ST; Pontes-Junior J; Antunes AA; de Sousa-Canavez JM; Dall'Oglio MF; Passerotti CC; Abe DK; Crippa A; da Cruz JA; Timoszczuk LM; Srougi M; Leite KR
Int J Biol Markers; 2011; 26(4):255-61. PubMed ID: 22139647
[TBL] [Abstract] [Full Text] [Related]
10. Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients.
Oh WK; Vargas R; Jacobus S; Leitzel K; Regan MM; Hamer P; Pierce K; Brown-Shimer S; Carney W; Ali SM; Kantoff PW; Lipton A
Cancer; 2011 Feb; 117(3):517-25. PubMed ID: 20862742
[TBL] [Abstract] [Full Text] [Related]
11. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review.
Jezierska A; Motyl T
Med Sci Monit; 2009 Feb; 15(2):RA32-40. PubMed ID: 19182722
[TBL] [Abstract] [Full Text] [Related]
12. Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer.
De Cicco C; Ravasi L; Zorzino L; Sandri MT; Botteri E; Verweij F; Granchi D; de Cobelli O; Paganelli G
Curr Cancer Drug Targets; 2008 May; 8(3):199-206. PubMed ID: 18473733
[TBL] [Abstract] [Full Text] [Related]
13. Tissue inhibitor of metalloproteinases 1 regulation of interleukin-10 in B-cell differentiation and lymphomagenesis.
Guedez L; Mansoor A; Birkedal-Hansen B; Lim MS; Fukushima P; Venzon D; Stetler-Stevenson WG; Stetler-Stevenson M
Blood; 2001 Mar; 97(6):1796-802. PubMed ID: 11238122
[TBL] [Abstract] [Full Text] [Related]
14. Erythropoietin in urologic oncology.
Albers P; Heicappell R; Schwaibold H; Wolff J;
Eur Urol; 2001 Jan; 39(1):1-8. PubMed ID: 11173931
[TBL] [Abstract] [Full Text] [Related]
